Outpatient antibiotic prescribing practices for uncomplicated urinary tract infection in women in the United States, 2002-2011

Open Forum Infectious Diseases

Volumn 3, Issue 3, 2016, Pages

  Kobayashi, Miwako ^a,b   Shapiro, Daniel J ^d   Hersh, Adam L ^e   Sanchez, Guillermo V ^c   Hicks, Lauri A ^c  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse drug event; Fluoroquinolone; Outpatient antibiotic stewardship; Uncomplicated urinary tract infection

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; LEVOFLOXACIN; NITROFURANTOIN; QUINOLONE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; DESCRIPTIVE RESEARCH; FEMALE; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTPATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; UNITED STATES; URINARY TRACT INFECTION;

EID: 85016019025     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw159     Document Type: Article

References (39)

1. Niska R, Bhuiya F, Xu J. National hospital ambulatory medical care survey: 2007 emergency department summary. Natl Health Stat Report 2010; 26:1-31.
2. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother 2014; 69:234-40.
3. Caterino JM, Weed SG, Espinola JA, Camargo CA Jr. National trends in emergency department antibiotic prescribing for elders with urinary tract infection, 1996-2005 Acad Emerg Med 2009; 16:500-7.
4. Kallen AJ, Welch HG, Sirovich BE. Current antibiotic therapy for isolated urinary tract infections in women. Arch Intern Med 2006; 166:635-9.
5. May L, Mullins P, Pines J. Demographic and treatment patterns for infections in ambulatory settings in the United States, 2006-2010. Acad Emerg Med 2014; 21:17-24.
6. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection. Clin Infect Dis 2007; 44:769-74.
7. DalhoffA. Resistance surveillance studies: a multifaceted problem-the fluoroquinolone example. Infection 2012; 40:239-62.
8. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010 Antimicrob Agents Chemother 2012; 56:2181-3.
9. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29:745-58.
10. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103-20.
11. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-34.
12. Kallen AJ, Thompson A, Ristaino P, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 2009; 30:264-72.
13. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60.
14. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68:1951-61.
15. Centers for Disease Control and Prevention. Ambulatory Health Care Data. Available at: http://www.cdc.gov/nchs/ahcd.htm. Accessed 11 March 2015.
16. Centers for Disease Control and Prevention National Center for Health Statistics. Ambulatory Health Care Data. Scope and Sample Design. Available at: http://www.cdc.gov/nchs/ahcd/ahcd_scope.htm#namcs_scope. Accessed 6 January 2016.
17. Centers for Disease Control and Prevention. Ambulatory Health Care Data. Trend Analysis Using NAMCS and NHAMCS Drug Data. Available at: http://www.cdc. gov/nchs/ahcd/trend_analysis.htm. Accessed 15 March 2016.
18. Huang ES, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med 2002; 162:41-7.
19. Sanchez GV, Baird AM, Karlowsky JA, et al. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients. J Antimicrob Chemother 2014; 69:3259-62.
20. Lode HM. Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes. Int J Antimicrob Agents 2014; 43:497-507.
21. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents 2009; 34:82-5.
22. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threatreport-2013/index.html. Accessed 5 February 2015.
23. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41(Suppl 2):S144-57.
24. FDA Drug Safety Communication. FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. In: US Food and Drug Administration, Press Release. May 12, 2016.
25. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38(Suppl 4):S341-5.
26. Mavromanolakis E, Maraki S, Samonis G, et al. Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. J Chemother 1997; 9:203-7.
27. Stewardson AJ, Gaia N, Francois P, et al. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota. Clin Microbiol Infect 2015; 21:344.e1-11.
28. Sanchez GV, Adams SJ, Baird AM, et al. Escherichia coli antimicrobial resistance increased faster among geriatric outpatients compared with adult outpatients in the USA, 2000-10. J Antimicrob Chemother 2013; 68:1838-41.
29. The American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015: updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015; 63:2227-46.
30. Sprague L. The Star Rating System and Medicare Advantage Plans. Issue Brief Natl Health Policy Forum 2015; 854. Available at: https://www.nhpf.org/library/details. cfm/2988. Accessed 1 July 2016.
31. Center for Medicare & Medicaid Services. Use of high risk medications in the Elderly (DAE). Available at: https://www.cms.gov/medicare/medicare-feefor-service-payment/physicianfeedbackprogram/downloads/elderly-high-riskmedications-dae.pdf. Accessed 1 July 2016.
32. Center of Medicare & Medicaid Services. Drug lists for "use of high risk medications in the elderly": measure in the 2012 group practice quality and resource use reports. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/PY2012-High-Risk-Meds.pdf. Accessed 1 July 2016.
33. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012; 33:322-7.
34. Lagerlov P, Loeb M, Andrew M, Hjortdahl P. Improving doctors' prescribing behaviour through reflection on guidelines and prescription feedback: a randomised controlled study. Qual Health Care 2000; 9:159-65
35. Lundborg CS, Wahlstrom R, Oke T, et al. Influencing prescribing for urinary tract infection and asthma in primary care in Sweden: a randomized controlled trial of an interactive educational intervention. J Clin Epidemiol 1999; 52:801-12.
36. Braybrook S, Walker R. Influencing prescribing in primary care: a comparison of two different prescribing feedback methods. J Clin Pharm Ther 1996; 21:247-54.
37. Peterson GM, Stanton LA, Bergin JK, Chapman GA. Improving the prescribing of antibiotics for urinary tract infection. J Clin Pharm Ther 1997; 22:147-53.
38. The White House. Combating antibiotic-resistant bacteria. Executive Order 13676 of September 18, 2014. 79 RF 56931. Available at: https://www.gpo.gov/fdsys/pkg/FR-2014-09-23/pdf/2014-22805.pdf. Accessed 6 January 2016.
39. Ewen E, Willey VJ, Kolm P, et al. Antibiotic prescribing by telephone in primary care. Pharmacoepidemiol Drug Saf 2015; 24:113-20.